South Korea's Pharma Producers Focus on Biosimilar Expansions

KOFU, JAPAN--April 19, 2021--Researched by Industrial Info Resources (Sugar Land, Texas)--South Korea's largest pharmaceutical companies are focusing on producing biosimilar products. Samsung Biologics, Celltrion and Prestige Biologics are expanding their production facilities with $1.66 billion worth of projects, and other mid-sized companies are expected to focus on developing and producing biosimilars with an eye on both domestic and export markets.